

Alvaro Pascual

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6545558/publications.pdf>

Version: 2024-02-01

428
papers

18,475
citations

13865
67
h-index

21540
114
g-index

478
all docs

478
docs citations

478
times ranked

13381
citing authors

#	ARTICLE	IF	CITATIONS
1	In vitro activity of six biocides against carbapenemase-producing <i>Klebsiella pneumoniae</i> and presence of genes encoding efflux pumps. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> , 2022, 40, 371-376.	0.5	3
2	Role of inorganic phosphate concentrations in in vitro activity of fosfomycin. <i>Clinical Microbiology and Infection</i> , 2022, 28, 302.e1-302.e4.	6.0	1
3	Transfer of plasmids harbouring blaOXA-48-like carbapenemase genes in biofilm-growing <i>Klebsiella pneumoniae</i> : Effect of biocide exposure. <i>Microbiological Research</i> , 2022, 254, 126894.	5.3	2
4	Higher prevalence of CTX-M-27-producing <i>Escherichia coli</i> belonging to ST131 clade C1 among residents of two long-term care facilities in Southern Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 335-338.	2.9	3
5	Development of an Anti- <i>Acinetobacter baumannii</i> Biofilm Phage Cocktail: Genomic Adaptation to the Host. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0192321.	3.2	12
6	< i>In Vitro</i> Activity of Cefepime-Taniborbactam against Carbapenemase-Producing < i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i> Isolates Recovered in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0216121.	3.2	22
7	Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant < i>Escherichia coli</i> Bacteremic Urinary Tract Infections. <i>JAMA Network Open</i> , 2022, 5, e2137277.	5.9	28
8	Reporting antimicrobial susceptibilities and phenotypes of resistance to vancomycin in vancomycin-resistant <i>Enterococcus</i> spp. clinical isolates: A nationwide proficiency study. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> , 2022, , .	0.5	1
9	Adaptation of clinical isolates of < i>Klebsiella pneumoniae</i> to the combination of niclosamide with the efflux pump inhibitor phenyl-arginine-β-naphthylamide (PaβN): co-resistance to antimicrobials. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1272-1281.	3.0	8
10	Molecular characterisation of an outbreak of NDM-7-producing <i>Klebsiella pneumoniae</i> reveals ST11 clone expansion combined with interclonal plasmid dissemination. <i>International Journal of Antimicrobial Agents</i> , 2022, , 106551.	2.5	0
11	The role of PemIK (PemK/PemI) type II TA system from <i>Klebsiella pneumoniae</i> clinical strains in lytic phage infection. <i>Scientific Reports</i> , 2022, 12, 4488.	3.3	17
12	Phenotypic and Genomic Comparison of <i>Klebsiella pneumoniae</i> Lytic Phages: vB_KpnM-VAC66 and vB_KpnM-VAC13. <i>Viruses</i> , 2022, 14, 6.	3.3	13
13	Effect of RecA inactivation and detoxification systems on the evolution of ciprofloxacin resistance in < i>Escherichia coli</i>. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 641-645.	3.0	5
14	Potential clinical significance of statins on methicillin resistance reversion in <i>Staphylococcus aureus</i> . <i>Enfermedades Infectuosas Y Microbiología Clinica (English Ed)</i> , 2022, 40, 214-215.	0.3	0
15	The role of the microbiology laboratory in the diagnosis of multidrug-resistant Gram-negative bacilli infections. The importance of figuring out resistance mechanisms. <i>Medicina Intensiva (English) Tj ETQq1 1 0.7843142gBT /Overlock 10</i>		
16	Extended-spectrum β-lactamase-producing and carbapenem-resistant <i>Enterobacteriales</i> bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	5
17	Characterization of Extended-Spectrum β-Lactamase-Producing <i>Shigella sonnei</i> in Spain: Expanding the Geographic Distribution of Sequence Type 152/CTX-M-27 Clone. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	3
18	Identification of a Stable Chromosomal Tandem Multicopy of < i>bla</i> < sub>VIM-63</sub>, a New < i>bla</i> < sub>VIM-2</sub> Carbapenemase. <i>Journal of Bacteriology</i> , 2022, 204, .	2.2	1

#	ARTICLE	IF	CITATIONS
19	Effect of RecA inactivation on quinolone susceptibility and the evolution of resistance in clinical isolates of <i>< i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 338-344.	3.0	7
20	SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load. <i>Journal of Infection</i> , 2021, 82, e38-e41.	3.3	16
21	Efficacy of β -lactam/ β -lactamase inhibitors to treat extended-spectrum beta-lactamase-producing <i>< i>Enterobacteriales</i> bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project). <i>Transplant Infectious Disease</i> , 2021, 23, e13520.	1.7	10
22	CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant <i>Enterobacteriales</i> . <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlaa112.	2.1	18
23	Reporting antimicrobial susceptibilities and resistance phenotypes in <i>< i>Staphylococcus</i> spp.: a nationwide proficiency study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1187-1196.	3.0	4
24	Interplay among Different Fosfomycin Resistance Mechanisms in <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	7
25	Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by <i>Enterobacteriaceae</i> . <i>Antibiotics</i> , 2021, 10, 348.	3.7	3
26	Do specific antimicrobial stewardship interventions have an impact on carbapenem resistance in Gram-negative bacilli? A multicentre quasi-experimental ecological study: time-trend analysis and characterization of carbapenemases. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1928-1936.	3.0	16
27	Efficacy of Fosfomycin and Its Combination With Aminoglycosides in an Experimental Sepsis Model by Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Clinical Strains. <i>Frontiers in Medicine</i> , 2021, 8, 615540.	2.6	5
28	Synergistic Quinolone Sensitization by Targeting the <i>< i>recA</i> SOS Response Gene and Oxidative Stress. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	8
29	Disbalancing Envelope Stress Responses as a Strategy for Sensitization of <i>Escherichia coli</i> to Antimicrobial Agents. <i>Frontiers in Microbiology</i> , 2021, 12, 653479.	3.5	1
30	Activity of Fosfomycin and Amikacin against Fosfomycin-Heteroresistant <i>Escherichia coli</i> Strains in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	3
31	Chromosomal positioning in spermatogenic cells is influenced by chromosomal factors associated with gene activity, bouquet formation and meiotic sex chromosome inactivation. <i>Chromosoma</i> , 2021, 130, 163-175.	2.2	1
32	Ertapenem for treatment of non-severe bacteremic urinary-tract infections due to ESBL-producing <i>Enterobacteriales</i> in kidney transplant recipients: a propensity score and DOOR-based analysis.. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0110221.	3.2	2
33	Enhanced Antibacterial Activity of Repurposed Mitomycin C and Imipenem in Combination with the Lytic Phage vB_KpnM-VAC13 against Clinical Isolates of <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0090021.	3.2	20
34	Household acquisition and transmission of extended-spectrum β -lactamase (ESBL) -producing <i>Enterobacteriaceae</i> after hospital discharge of ESBL-positive index patients. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1322-1329.	6.0	14
35	In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO-WT 2014-2018 studies in Spain. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 26, 292-300.	2.2	11
36	Increased Blood Monocytic Myeloid Derived Suppressor Cells but Low Regulatory T Lymphocytes in Patients with Mild COVID-19. <i>Viral Immunology</i> , 2021, 34, 639-645.	1.3	13

#	ARTICLE	IF	CITATIONS
37	Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant <i>Enterobacteriales</i> (ASTART): protocol for a randomised, pragmatic trial. <i>BMJ Open</i> , 2021, 11, e049481.	1.9	6
38	Successful outcome after treatment with a combination of meropenem and fosfomycin for VIM-1 and CTX-M-15 producing <i>Klebsiella pneumoniae</i> bloodstream infection. <i>Journal of Infection</i> , 2021, 83, e12-e13.	3.3	0
39	Co-transfer of plasmid-encoded bla carbapenemases genes and mercury resistance operon in high-risk clones of <i>Klebsiella pneumoniae</i> . <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 9231-9242.	3.6	8
40	Potential clinical significance of statins on methicillin resistance reversion in <i>Staphylococcus aureus</i> . <i>Enfermedades Infectuosas Y Microbiología Clínica</i> , 2021, 40, 214-214.	0.5	0
41	Interplay between IncF plasmids and topoisomerase mutations conferring quinolone resistance in the <i>Escherichia coli</i> ST131 clone: stability and resistance evolution. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, , 1.	2.9	0
42	Multicenter Performance Evaluation of MALDI-TOF MS for Rapid Detection of Carbapenemase Activity in Enterobacteriales: The Future of Networking Data Analysis With Online Software. <i>Frontiers in Microbiology</i> , 2021, 12, 789731.	3.5	4
43	Outcomes of the PIRASOA programme, an antimicrobial stewardship programme implemented in hospitals of the Public Health System of Andalusia, Spain: an ecologic study of time-trend analysis. <i>Clinical Microbiology and Infection</i> , 2020, 26, 358-365.	6.0	30
44	Reply to Woerther et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 1129-1130.	5.8	0
45	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacteriales: The impact of cytomegalovirus disease and lymphopenia. <i>American Journal of Transplantation</i> , 2020, 20, 1629-1641.	4.7	17
46	First identification of blaNDM-1 carbapenemase in blaOXA-94-producing <i>Acinetobacter baumannii</i> ST85 in Spain. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> , 2020, 38, 11-15.	0.5	23
47	Assessment of a semi-automated enrichment system (Uroquattro HB&L) for detection of faecal carriers of ESBL/AmpC-producing Enterobacteriales. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> , 2020, 38, 367-370.	0.5	1
48	Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> (English Ed), 2020, 38, 182-187.	0.3	0
49	Detection of Low-Level Fosfomycin-Resistant Variants by Decreasing Glucose-6-Phosphate Concentration in Fosfomycin Susceptibility Determination. <i>Antibiotics</i> , 2020, 9, 802.	3.7	7
50	Characterization of NDM-1- and CMH-3-producing <i>Enterobacter cloacae</i> complex ST932 in a patient transferred from Ukraine to Spain. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> (English Ed), 2020, 38, 327-330.	0.3	0
51	WGS characterization of MDR Enterobacteriales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa084.	2.1	7
52	Mechanisms of Tolerance and Resistance to Chlorhexidine in Clinical Strains of <i>Klebsiella pneumoniae</i> Producers of Carbapenemase: Role of New Type II Toxin-Antitoxin System, PemIK. <i>Toxins</i> , 2020, 12, 566.	3.4	15
53	Role of low-level quinolone resistance in generating tolerance in <i>Escherichia coli</i> under therapeutic concentrations of ciprofloxacin. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2124-2132.	3.0	9
54	Nosocomial outbreak linked to a flexible gastrointestinal endoscope contaminated with an amikacin-resistant ST17 clone of <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1837-1844.	2.9	11

#	ARTICLE	IF	CITATIONS
55	Contribution of hypermutation to fosfomycin heteroresistance in <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2066-2075.	3.0	6
56	First identification of blaNDM-1 carbapenemase in blaOXA-94-producing <i>Acinetobacter baumannii</i> ST85 in Spain. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2020, 38, 11-15.	0.3	0
57	In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. <i>Scientific Reports</i> , 2020, 10, 7163.	3.3	54
58	Evolution of the antimicrobial resistance rates in clinical isolates of <i>Pseudomonas aeruginosa</i> causing invasive infections in the south of Spain. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2020, 38, 150-154.	0.3	0
59	Activity of cefiderocol against high-risk clones of multidrug-resistant <i>Enterobacteriales</i> , <i>Acinetobacter baumannii</i> , <i>Pseudomonas aeruginosa</i> and <i>Stenotrophomonas maltophilia</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1840-1849.	3.0	81
60	EvoluciÃ³n de la resistencia antimicrobiana en aislados clÃnicos de <i>Pseudomonas aeruginosa</i> productores de infecciones invasivas en el sur de EspaÃ±a. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2020, 38, 150-154.	0.5	3
61	Characterization of NDM-1- and CMH-3-producing <i>Enterobacter cloacae</i> complex ST932 in a patient transferred from Ukraine to Spain. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2020, 38, 327-330.	0.5	7
62	Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of <i>Klebsiella pneumoniae</i> . <i>Microbial Genomics</i> , 2020, 6, .	2.0	21
63	Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2020, 38, 182-187.	0.5	6
64	Assessment of a semi-automated enrichment system (Uroquattro HB&L) for detection of faecal carriers of ESBL-/AmpC-producing <i>Enterobacteriales</i> . <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2020, 38, 367-370.	0.3	0
65	Suppression of the SOS response modifies spatiotemporal evolution, post-antibiotic effect, bacterial fitness and biofilm formation in quinolone-resistant <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 66-73.	3.0	17
66	Predictive value of the kinetics of procalcitonin and C-reactive protein for early clinical stability in patients with bloodstream infections due to Gram-negative bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 63-68.	1.8	11
67	External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteraemia cohort: the prognostic significance of colistin resistance. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 442-448.	2.5	11
68	Microbiological diagnostics of bloodstream infections in Europeâ€”an ESCBIES survey. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1399-1407.	6.0	35
69	Extended-spectrum β -lactamase-producing <i>Enterobacteriaceae</i> from animal origin and wastewater in Tunisia: first detection of O25b-B23-CTX-M-27-ST131 <i>Escherichia coli</i> and CTX-M-15/OXA-204-producing <i>Citrobacter freundii</i> from wastewater. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 17, 189-194.	2.2	48
70	Comparative activity of a polyhexanideâ€“betaine solution against biofilms produced by multidrug-resistant bacteria belonging to high-risk clones. <i>Journal of Hospital Infection</i> , 2019, 103, e92-e96.	2.9	17
71	Reporting identification of <i>Acinetobacter</i> spp genomic species: A nationwide proficiency study in Spain. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2019, 37, 89-92.	0.3	0
72	Combined Use of the Ab105-2Î²CI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant <i>Acinetobacter baumannii</i> . <i>Microorganisms</i> , 2019, 7, 556.	3.6	33

#	ARTICLE	IF	CITATIONS
73	Rhodomyrtone decreases <i>Staphylococcus aureus</i> SigB activity during exponentially growing phase and inhibits haemolytic activity within membrane vesicles. <i>Microbial Pathogenesis</i> , 2019, 128, 112-118.	2.9	11
74	OXA-48-Like-Producing <i>Klebsiella pneumoniae</i> in Southern Spain in 2014–2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	23
75	Impact of De-escalation on Prognosis of Patients With Bacteremia due to Enterobacteriaceae: A Post Hoc Analysis From a Multicenter Prospective Cohort. <i>Clinical Infectious Diseases</i> , 2019, 69, 956-962.	5.8	18
76	Vagino-rectal colonization and maternal–neonatal transmission of Enterobacteriaceae producing extended-spectrum β -lactamases or carbapenemases: a cross-sectional study. <i>Journal of Hospital Infection</i> , 2019, 101, 167-174.	2.9	21
77	Reporting identification of <i>Acinetobacter</i> spp genomic species: A nationwide proficiency study in Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 89-92.	0.5	0
78	Relationship between Tolerance and Persistence Mechanisms in <i>Acinetobacter baumannii</i> Strains with AbkAB Toxin-Antitoxin System. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
79	Reporting antimicrobial susceptibilities and resistance phenotypes in <i>Acinetobacter</i> spp: a nationwide proficiency study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 692-697.	3.0	13
80	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>< i>Escherichia coli</i></i> and ESBL-Producing <i>< i>Klebsiella pneumoniae</i></i> . <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 660-667.	1.8	49
81	Population pharmacokinetics and pharmacodynamics of fosfomycin in non-“critically ill patients with bacteremic urinary infection caused by multidrug-resistant <i>Escherichia coli</i> . <i>Clinical Microbiology and Infection</i> , 2018, 24, 1177-1183.	6.0	18
82	Evolution of the Quorum network and the mobilome (plasmids and bacteriophages) in clinical strains of <i>Acinetobacter baumannii</i> during a decade. <i>Scientific Reports</i> , 2018, 8, 2523.	3.3	28
83	Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. <i>Clinical Microbiology Reviews</i> , 2018, 31, .	13.6	486
84	Susceptibility testing and detection of β -lactam resistance mechanisms in Enterobacteriaceae: a multicentre national proficiency study. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 612-619.	2.5	6
85	Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. <i>Transplantation Reviews</i> , 2018, 32, 36-57.	2.9	104
86	Urinary Tract Conditions Affect Fosfomycin Activity against <i>Escherichia coli</i> Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	22
87	Direct bacterial identification from positive blood cultures using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry: A systematic review and meta-analysis. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 484-492.	0.5	21
88	Prevalence of Aminoglycoside-Modifying Enzymes in <i>< i>Escherichia coli</i></i> and <i>< i>Klebsiella pneumoniae</i></i> Producing Extended Spectrum β -Lactamases Collected in Two Multicenter Studies in Spain. <i>Microbial Drug Resistance</i> , 2018, 24, 367-376.	2.0	26
89	Prevalence and transmission dynamics of <i>Escherichia coli</i> ST131 among contacts of infected community and hospitalized patients. <i>Clinical Microbiology and Infection</i> , 2018, 24, 618-623.	6.0	19
90	Duration of Colonization by Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae in Healthy Newborns and Associated Risk Factors: A Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy312.	0.9	5

#	ARTICLE	IF	CITATIONS
91	Intestinal colonization due to <i>Escherichia coli</i> ST131: risk factors and prevalence. <i>Antimicrobial Resistance and Infection Control</i> , 2018, 7, 135.	4.1	18
92	Relationship Between the Quorum Network (Sensing/Quenching) and Clinical Features of Pneumonia and Bacteraemia Caused by <i>A. baumannii</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 3105.	3.5	14
93	Incidence and Risk Factors for Acquisition of Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae in Newborns in Seville, Spain: A Prospective Cohort Study. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 835-841.	2.5	5
94	Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent <i>Clostridium difficile</i> Infection in High-Risk Patients in Spain. <i>Advances in Therapy</i> , 2018, 35, 1920-1934.	2.9	17
95	Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β -lactamase-producing Enterobacteriaceae. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 577-585.	2.5	36
96	Application of BioFire FilmArray Blood Culture Identification panel for rapid identification of the causative agents of ventilator-associated pneumonia. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1213.e1-1213.e4.	6.0	29
97	Efficacy of Colistin and Its Combination With Rifampin in Vitro and in Experimental Models of Infection Caused by Carbapenemase-Producing Clinical Isolates of <i>Klebsiella pneumoniae</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 912.	3.5	16
98	Prevalence of ST131 Clone Producing Both ESBL CTX-M-15 and AAC(6'')Ib-cr Among Ciprofloxacin-Resistant <i>Escherichia coli</i> Isolates from Yemen. <i>Microbial Drug Resistance</i> , 2018, 24, 1537-1542.	2.0	10
99	Characterization of Plasmid-Mediated Quinolone Resistance Determinants in High-Level Quinolone-Resistant <i>Enterobacteriaceae</i> Isolates from the Community: First Report of <i>qnrD</i> Gene in Algeria. <i>Microbial Drug Resistance</i> , 2017, 23, 90-97.	2.0	12
100	IdentificaciÃ³n y determinaciÃ³n de sensibilidad a antibÃ³ticos de aislados de hemocultivos a partir de subcultivos de corta incubaciÃ³n. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2017, 35, 582-585.	0.5	5
101	In vitro activity of a polyhexanide-betaine solution against high-risk clones of multidrug-resistant nosocomial pathogens. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2017, 35, 12-19.	0.5	17
102	Molecular insights into fosfomycin resistance in <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw573.	3.0	29
103	Plasmidic <i>qnr</i> Genes Confer Clinical Resistance to Ciprofloxacin under Urinary Tract Physiological Conditions. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	8
104	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- β -lactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw513.	3.0	46
105	Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae. <i>Clinical Microbiology and Infection</i> , 2017, 23, 325-331.	6.0	38
106	Baja prevalencia de aislados mcr -1 positivos en enterobacterias en nuestra Ã¡rea. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2017, 35, 467-468.	0.5	1
107	Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2017, 35, 499-504.	0.5	13
108	Rapid detection of the plasmid-mediated quinolone resistance determinant AAC(6'')-Ib-cr in Enterobacteriaceae by MALDI-TOF MS analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw552.	3.0	7

#	ARTICLE	IF	CITATIONS
109	In vitro activity of a polyhexanide-β-alanine solution against high-risk clones of multidrug-resistant nosocomial pathogens. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> (English Ed), 2017, 35, 12-19.	0.3	0
110	MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw562.	3.0	17
111	EUropean prospective cohort study on <i>Enterobacteriaceae</i> showing REsistance to CArbapenems (EURECA): a protocol of a European multicentre observational study. <i>BMJ Open</i> , 2017, 7, e015365.	1.9	22
112	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 726-734.	9.1	367
113	Molecular Characterization of Fluoroquinolone-Resistant<i>Haemophilus parainfluenzae</i> Clinical Isolates in Spain. <i>Microbial Drug Resistance</i> , 2017, 23, 935-939.	2.0	4
114	Overproduction of outer membrane protein A (OmpA) by <i>Acinetobacter baumannii</i> is a risk factor for nosocomial pneumonia, bacteremia and mortality increase.. <i>Journal of Infectious Diseases</i> , 2017, 215, jix010.	4.0	42
115	First report of NDM-1-producing clinical isolate of <i>Leclercia adecarboxylata</i> in Spain. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 268-270.	1.8	26
116	Molecular topology: A new strategy for antimicrobial resistance control. <i>European Journal of Medicinal Chemistry</i> , 2017, 137, 233-246.	5.5	11
117	High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2102-2109.	3.0	11
118	Bacteraemia due to non-ESBL-producing <i>Escherichia coli</i> O25b:H4 sequence type 131: insights into risk factors, clinical features and outcomes. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 498-502.	2.5	15
119	Cytotoxic Effect Associated with Overexpression of QNR Proteins in <i>Escherichia coli</i>. <i>Microbial Drug Resistance</i> , 2017, 23, 822-825.	2.0	1
120	Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> (English Ed), 2017, 35, 497-502.	0.3	0
121	Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1020-1021.	9.1	10
122	Quinolone Resistance Reversion by Targeting the SOS Response. <i>MBio</i> , 2017, 8, .	4.1	54
123	Quantitative and automated MALDI-TOF MS-based detection of the plasmid-mediated quinolone resistance determinant AAC(6'-Ib-cr) in Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2952-2954.	3.0	11
124	Prevalence of quinolone resistance mechanisms in Enterobacteriaceae producing acquired AmpC β-lactamases and/or carbapenemases in Spain. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> (English Ed), 2017, 35, 485-490.	0.3	4
125	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 664-672.	2.5	8
126	Occurrence of the Plasmid-Mediated Fluoroquinolone Resistance qepA1 Gene in Two Clonal Clinical Isolates of CTX-M-15-Producing <i>Escherichia coli</i> from Algeria. <i>Microbial Drug Resistance</i> , 2017, 23, 497-499.	2.0	3

#	ARTICLE	IF	CITATIONS
127	Prevalencia en España de mecanismos de resistencia a quinolonas en enterobacterias productoras de betalactamasas de clase C adquiridas y/o carbapenemasas. Enfermedades Infecciosas Y Microbiología Clínica, 2017, 35, 487-492.	0.5	8
128	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
129	Response to Bile Salts in Clinical Strains of <i>Acinetobacter baumannii</i> Lacking the AdeABC Efflux Pump: Virulence Associated with Quorum Sensing. Frontiers in Cellular and Infection Microbiology, 2017, 7, 143.	3.9	40
130	Cellular Response to Ciprofloxacin in Low-Level Quinolone-Resistant <i>Escherichia coli</i> . Frontiers in Microbiology, 2017, 8, 1370.	3.5	21
131	Quorum sensing network in clinical strains of <i>A. baumannii</i> : AidA is a new quorum quenching enzyme. PLoS ONE, 2017, 12, e0174454.	2.5	54
132	Genome Sequence of Airborne <i>Acinetobacter</i> sp. Strain 5-2Ac02 in the Hospital Environment, Close to the Species of <i>Acinetobacter towneri</i> . Genome Announcements, 2016, 4, .	0.8	4
133	Modelling the epidemiology of <i>Escherichia coli</i> ST131 and the impact of interventions on the community and healthcare centres. Epidemiology and Infection, 2016, 144, 1974-1982.	2.1	11
134	Characterization of an outbreak due to CTX-M-15-producing <i>Klebsiella pneumoniae</i> lacking the <i>bla</i> _{OXA-48} gene belonging to clone ST405 in a neonatal unit in southern Spain. Journal of Antimicrobial Chemotherapy, 2016, 71, 2353-2355.	3.0	16
135	Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant <i>Escherichia coli</i> . Antimicrobial Agents and Chemotherapy, 2016, 60, 4252-4258.	3.2	20
136	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
137	Plasmid-mediated quinolone resistance: Two decades on. Drug Resistance Updates, 2016, 29, 13-29.	14.4	153
138	First report of the plasmid-mediated colistin resistance gene mcr-1 in a clinical <i>Escherichia coli</i> isolate in Algeria. International Journal of Antimicrobial Agents, 2016, 48, 760-761.	2.5	27
139	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
140	Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory <i>Pseudomonas aeruginosa</i> Isolates Expressing Combinations of Most Relevant β -Lactam Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2016, 60, 6407-6410.	3.2	47
141	Impact of AAC(6'-Ib-cr) in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in <i>Escherichia coli</i> . Journal of Antimicrobial Chemotherapy, 2016, 71, 3066-3071.	3.0	39
142	CTX-M-15- <i>H</i> 30Rx-ST131 subclone is one of the main causes of healthcare-associated ESBL-producing <i>Escherichia coli</i> bacteraemia of urinary origin in Spain. Journal of Antimicrobial Chemotherapy, 2016, 71, 2125-2130.	3.0	46
143	Genomic Evolution of Two <i>Acinetobacter baumannii</i> Clinical Strains from ST-2 Clones Isolated in 2000 and 2010 (ST-2_clon_2000 and ST-2_clon_2010). Genome Announcements, 2016, 4, .	0.8	6
144	Clinical characteristics, treatment and outcomes of MRSA bacteraemia in the elderly. Journal of Infection, 2016, 72, 309-316.	3.3	11

#	ARTICLE	IF	CITATIONS
145	Acinetobacter baumannii in critically ill patients: Molecular epidemiology, clinical features and predictors of mortality. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 551-558.	0.5	23
146	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1672-1680.	3.0	41
147	Assessment of Chromosomal DNA Fragmentation by Quinolones in an Isogenic Collection of <i>Escherichia coli</i> with Defined Resistance Mechanisms. <i>Microbial Drug Resistance</i> , 2016, 22, 354-359.	2.0	6
148	Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 521-530.	3.0	21
149	First reported case of a corneal abscess caused by <i>Massilia timonae</i> . <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 212-213.	0.5	2
150	Assessment of a phenotypic algorithm to detect plasmid-mediated quinolone resistance in Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 845-847.	3.0	18
151	Comparison of clinical categories for <i>Escherichia coli</i> harboring specific qnr and chromosomal-mediated fluoroquinolone resistance determinants according to CLSI and EUCAST. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 188-190.	0.5	4
152	Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. <i>Journal of Infection</i> , 2016, 72, 152-160.	3.3	73
153	Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries. <i>Clinical Microbiology and Infection</i> , 2016, 22, 63.e1-63.e5.	6.0	38
154	Reduced Susceptibility to Cefepime in Clinical Isolates of <i>Enterobacteriaceae</i> Producing OXA-1 Beta-Lactamase. <i>Microbial Drug Resistance</i> , 2016, 22, 141-146.	2.0	18
155	Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) catheter-related bacteraemia in haemodialysis patients. <i>BMC Infectious Diseases</i> , 2015, 15, 484.	2.9	7
156	Challenges to accurate susceptibility testing and interpretation of quinolone resistance in Enterobacteriaceae: results of a Spanish multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2038-47.	3.0	6
157	Effect of the efflux pump QepA2 combined with chromosomally mediated mechanisms on quinolone resistance and bacterial fitness in <i>Escherichia coli</i> : Table A1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2524-2527.	3.0	32
158	Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β -lactams: a systematic review and meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 1751-1758.	2.9	6
159	Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of <i>Escherichia coli</i> resistant to amoxicillin/clavulanic acid isolated in Spain. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 157-163.	2.5	36
160	Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2652-2660.	3.0	19
161	Risk factors for severe sepsis in community-onset bacteraemic urinary tract infection: Impact of antimicrobial resistance in a large hospitalised cohort. <i>Journal of Infection</i> , 2015, 70, 247-254.	3.3	17
162	Prolonged treatment with large doses of fosfomycin plus vancomycin and amikacin in a case of bacteraemia due to methicillin-resistant <i>Staphylococcus epidermidis</i> and IMP-8 metallo- β -lactamase-producing <i>Klebsiella oxytoca</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 313-315.	3.0	14

#	ARTICLE	IF	CITATIONS
163	Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 337.e1-337.e21.	0.5	29
164	Executive summary of the diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 338-341.	0.5	23
165	Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 905-913.	3.0	91
166	Uncoupling between core genome and virulome in extraintestinal pathogenic <i>Escherichia coli</i> . <i>Canadian Journal of Microbiology</i> , 2015, 61, 647-652.	1.7	3
167	Fosfomycin Versus Meropenem In Bacteremic Urinary Tract Infections Caused By Extended-Spectrum Beta-lactamase Producing <i>Escherichia Coli</i> (Esbl-Ec): Forest Study. <i>Clinical Therapeutics</i> , 2015, 37, e34-e35.	2.5	1
168	Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5602-5610.	3.2	87
169	Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of <i>Escherichia coli</i> isolates with characterized resistance phenotypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2306-2310.	3.0	14
170	Antimicrobial photodynamic activity of hypericin against methicillin-susceptible and resistant <i>Staphylococcus aureus</i> biofilms. <i>Future Microbiology</i> , 2015, 10, 347-356.	2.0	74
171	Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β -lactamase-producing <i>Escherichia coli</i> (FOREST): study protocol for an investigator-driven randomised controlled trial. <i>BMJ Open</i> , 2015, 5, e007363-e007363.	1.9	61
172	First report of linezolid dependence in methicillin-resistant <i>Staphylococcus aureus</i> . <i>Clinical Microbiology and Infection</i> , 2015, 21, 650.e1-650.e4.	6.0	9
173	Executive summary of the diagnosis and treatment of bacteremia and endocarditis due to <i>Staphylococcus aureus</i> . A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 626-632.	0.5	34
174	Diagnosis and treatment of bacteremia and endocarditis due to <i>Staphylococcus aureus</i> . A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 625.e1-625.e23.	0.5	32
175	Prospective Multicenter Study of Carbapenemase-Producing Enterobacteriaceae from 83 Hospitals in Spain Reveals High <i>In Vitro</i> Susceptibility to Colistin and Meropenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3406-3412.	3.2	130
176	Reduced susceptibility to biocides in <i>Acinetobacter baumannii</i> : association with resistance to antimicrobials, epidemiological behaviour, biological cost and effect on the expression of genes encoding porins and efflux pumps. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3222-3229.	3.0	65
177	Minimum requirements in infection control. <i>Clinical Microbiology and Infection</i> , 2015, 21, 1072-1076.	6.0	20
178	Description of the OXA-23 β -Lactamase Gene Located Within Tn<i>2007</i> in a Clinical Isolate of <i>Acinetobacter baumannii</i> from Spain. <i>Microbial Drug Resistance</i> , 2015, 21, 215-217.	2.0	15
179	Lessons from an outbreak of metallo- β -lactamase-producing <i>Klebsiella oxytoca</i> in an intensive care unit: the importance of time at risk and combination therapy. <i>Journal of Hospital Infection</i> , 2015, 89, 123-131.	2.9	23
180	Global dissemination of a multidrug resistant <i>Escherichia coli</i> clone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 5694-5699.	7.1	498

#	ARTICLE	IF	CITATIONS
181	Carbapenemase-producing Enterobacteriaceae: The end of the antibiotic era?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2014, 32, 1-3.	0.5	8
182	Lack of association between genotypes and haematogenous seeding infections in a large cohort of patients with methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia from 21 Spanish hospitals. <i>Clinical Microbiology and Infection</i> , 2014, 20, 361-367.	6.0	14
183	Characterisation of the first ongoing outbreak due to KPC-3-producing <i>Klebsiella pneumoniae</i> (ST512) in Spain. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 538-540.	2.5	46
184	Presence of quinolone resistance to qnrB1 genes and blaOXA-48 carbapenemase in clinical isolates of <i>Klebsiella pneumoniae</i> in Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2014, 32, 441-442.	0.5	18
185	Characterization of plasmids carrying the blaOXA-24/40 carbapenemase gene and the genes encoding the AbkA/AbkB proteins of a toxin/antitoxin system*. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2629-2633.	3.0	43
186	Interplay between plasmid-mediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3203-3215.	3.0	76
187	Within-lineage variability of ST131 <i>Escherichia coli</i> isolates from humans and companion animals in the south of Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 271-273.	3.0	17
188	Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant <i>Staphylococcus aureus</i> persistent bacteraemia treated with daptomycin. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 568-571.	3.0	56
189	<i>Escherichia coli</i> belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 809-814.	3.0	52
190	Monotherapy versus combination therapy for sepsis due to multidrug-resistant <i>Acinetobacter baumannii</i> : analysis of a multicentre prospective cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3119-3126.	3.0	81
191	First detection and characterization of an OXA-48-producing <i>Enterobacter aerogenes</i> isolate. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2014, 32, 469-470.	0.5	8
192	Epidemiologic and Clinical Impact of <i>Acinetobacter baumannii</i> Colonization and Infection. <i>Medicine (United States)</i> , 2014, 93, 202-210.	1.0	53
193	Scientific evidence and research in antimicrobial stewardship. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 56-61.	0.5	4
194	Wastewater drainage system as an occult reservoir in a protracted clonal outbreak due to metallo-β-lactamase-producing <i>Klebsiella oxytoca</i> . <i>Clinical Microbiology and Infection</i> , 2013, 19, E490-E498.	6.0	104
195	Outcome of bacteraemia due to extended-spectrum β-lactamase-producing <i>Escherichia coli</i> : Impact of microbiological determinants. <i>Journal of Infection</i> , 2013, 67, 27-34.	3.3	22
196	Contribution of Efflux Pumps, Porins, and β-Lactamases to Multidrug Resistance in Clinical Isolates of <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5247-5257.	3.2	170
197	Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by <i>Escherichia coli</i> with or without the GyrA mutation Ser83Leu. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1609-1615.	3.0	29
198	Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 253-259.	2.9	91

#	ARTICLE	IF	CITATIONS
199	Antimicrobial stewardship programs: A public health priority in Spain. The SEIMC-REIPI initiative. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> , 2013, 31, 1-2.	0.5	5
200	Escherichia coli O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> , 2013, 31, 385-388.	0.5	22
201	Impact of an Evidence-Based Bundle Intervention in the Quality-of-Care Management and Outcome of <i>Staphylococcus aureus</i> Bacteremia. <i>Clinical Infectious Diseases</i> , 2013, 57, 1225-1233.	5.8	192
202	Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum- β -Lactamase-Producing Escherichia coli. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3402-3404.	3.2	90
203	Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and λ -haemolytic streptococci collected from western European countries in 2011. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 164-167.	3.0	35
204	Challenges for accurate susceptibility testing, detection and interpretation of λ -lactam resistance phenotypes in <i>Pseudomonas aeruginosa</i> : results from a Spanish multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 619-630.	3.0	20
205	Four Main Viotypes among Extended-Spectrum- β -Lactamase-Producing Isolates of Escherichia coli O25b:H4-B2-ST131: Bacterial, Epidemiological, and Clinical Characteristics. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3358-3367.	3.9	76
206	Clinical management of infections caused by multidrug-resistant <i>< i>Enterobacteriaceae</i></i> . <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 49-69.	1.8	50
207	Contribution of OqxAB efflux pumps to quinolone resistance in extended-spectrum- λ -lactamase-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 68-73.	3.0	106
208	Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum β -Lactamase (ESBL)-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2109-2113.	3.2	51
209	Epidemiological and Clinical Complexity of Amoxicillin-Clavulanate-Resistant Escherichia coli. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2414-2417.	3.9	13
210	Effect of Statin Therapy in the Outcome of Bloodstream Infections Due to <i>Staphylococcus aureus</i> : A Prospective Cohort Study. <i>PLoS ONE</i> , 2013, 8, e82958.	2.5	28
211	Genomewide Overexpression Screen for Fosfomycin Resistance in Escherichia coli: MurA Confers Clinical Resistance at Low Fitness Cost. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2767-2769.	3.2	48
212	Exposure to diverse antimicrobials induces the expression of qnrB1, qnrD and smaqrn genes by SOS-dependent regulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2854-2859.	3.0	32
213	Genetic characterization of an extended-spectrum AmpC cephalosporinase with hydrolysing activity against fourth-generation cephalosporins in a clinical isolate of <i>Enterobacter aerogenes</i> selected in vivo. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 64-68.	3.0	20
214	Spanish Multicenter Study of the Epidemiology and Mechanisms of Amoxicillin-Clavulanate Resistance in Escherichia coli. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3576-3581.	3.2	49
215	Daptomycin or Vancomycin for Methicillin-Resistant <i>Staphylococcus aureus</i> with a Vancomycin Minimum Inhibitory Concentration > 1 μ g/L. <i>Clinical Infectious Diseases</i> , 2012, 54, 1375-1376.	5.8	2
216	Prologue. <i>Enfermedades Infectuosas Y Microbiología Clínica</i> , 2012, 30, 1.	0.5	0

#	ARTICLE	IF	CITATIONS
217	Â-Lactam/Â-Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum Â-Lactamase-Producing <i>Escherichia coli</i> : A Post Hoc Analysis of Prospective Cohorts. <i>Clinical Infectious Diseases</i> , 2012, 54, 167-174.	5.8	329
218	Increased raw poultry meat colonization by extended spectrum beta-lactamase-producing <i>Escherichia coli</i> in the south of Spain. <i>International Journal of Food Microbiology</i> , 2012, 159, 69-73.	4.7	79
219	Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β -lactamase-producing <i>Escherichia coli</i> . <i>Clinical Microbiology and Infection</i> , 2012, 18, 894-900.	6.0	36
220	Production of a plasmid-encoded OXA-72 β -lactamase associated with resistance to carbapenems in a clinical isolate <i>Acinetobacter junii</i> . <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 93-94.	2.5	11
221	Prevalence of plasmid-mediated quinolone resistance determinants <i>qnr</i> and <i>aac(6â€¢)-Ib-cr</i> in <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> producing extended-spectrum β -lactamases in Spain. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 431-434.	2.5	107
222	Prevalence and analysis of microbiological factors associated with phenotypic heterogeneous resistance to carbapenems in <i>Acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 472-477.	2.5	23
223	Epidemiological and clinical features associated with colonisation/infection by <i>Acinetobacter baumannii</i> with phenotypic heterogeneous resistance to carbapenems. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 235-238.	2.5	14
224	Clinical and molecular epidemiology of meticillin-resistant <i>Staphylococcus aureus</i> causing bacteraemia in Southern Spain. <i>Journal of Hospital Infection</i> , 2012, 81, 257-263.	2.9	15
225	Prologue. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2012, 30, 1.	0.5	1
226	Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β -lactamases. <i>Journal of Infection</i> , 2012, 64, 176-183.	3.3	45
227	Virulence Profiles of Bacteremic Extended-Spectrum β -Lactamase-Producing <i>Escherichia coli</i> : Association with Epidemiological and Clinical Features. <i>PLoS ONE</i> , 2012, 7, e44238.	2.5	35
228	<i>Klebsiella pneumoniae</i> Strains Producing Extended-Spectrum β -Lactamases in Spain: Microbiological and Clinical Features. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1134-1136.	3.9	25
229	Discrepancies in fluoroquinolone clinical categories between the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI for <i>Escherichia coli</i> harbouring <i>qnr</i> genes and mutations in <i>gyrA</i> and <i>parC</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1405-1407.	3.0	13
230	Characterisation of clinical and food animal <i>Escherichia coli</i> isolates producing CTX-M-15 extended-spectrum β -lactamase belonging to ST410 phylogroup A. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 365-367.	2.5	44
231	Attenuated virulence of a slow-growing pandrug-resistant <i>Acinetobacter baumannii</i> is associated with decreased expression of genes encoding the porins <i>CarO</i> and <i>OprD-like</i> . <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 548-549.	2.5	31
232	Update on pathogenesis and diagnosis of intravascular catheter-related infections. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011, 29, 16-21.	0.5	12
233	Local imipenem activity against <i>Pseudomonas aeruginosa</i> decreases in vivo in the presence of siliconized latex. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 289-291.	2.9	3
234	Assessment of the presence of extended-spectrum beta-lactamase-producing <i>Escherichia coli</i> in eggshells and ready-to-eat products. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 1045-1047.	2.9	21

#	ARTICLE	IF	CITATIONS
235	Plasmid-mediated quinolone resistance: an update. <i>Journal of Infection and Chemotherapy</i> , 2011, 17, 149-182.	1.7	233
236	< i>In Vitro Effect of < i>qnrA1 , < i>qnrB1 , and < i>qnrS1 Genes on Fluoroquinolone Activity against Isogenic < i>Escherichia coli Isolates with Mutations in < i>gyrA and < i>parC . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1266-1269.	3.2	56
237	Comparative activity of carbapenem testing: the COMPACT study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1070-1078.	3.0	37
238	Evaluation of Three Automated Systems for Susceptibility Testing of Enterobacteria Containing qnrB, qnrS, and/or aac(6â€¢)-lb-cr. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3343-3345.	3.9	7
239	Molecular characterization of high-level fluoroquinolone resistance in a clinical isolate of Haemophilus parainfluenzae. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 673-675.	3.0	14
240	National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2011-2021.	3.0	117
241	Similarities between the genetic environments of blaCTX-M-15 in Escherichia coli from clinical and food samples from Spain and overseas travellers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2177-2177.	3.0	3
242	Analysis of Genes Encoding Penicillin-Binding Proteins in Clinical Isolates of Acinetobacter baumannii. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5907-5913.	3.2	49
243	A comprehensive surveillance, control and management programme for Clostridium difficile infection. <i>Journal of Hospital Infection</i> , 2010, 74, 91-93.	2.9	4
244	Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum ß-lactamase-producing and extended-spectrum ß-lactamase-non-producing Escherichia coli isolates.. <i>Clinical Microbiology and Infection</i> , 2010, 16, 132-136.	6.0	71
245	Extended-spectrum and CMY-type b-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. <i>Clinical Microbiology and Infection</i> , 2010, 16, 33-38.	6.0	133
246	Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum-ß-Lactamase-Producing < i>Escherichia coli. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1726-1731.	3.9	144
247	Antimicrobial Resistance among Respiratory Pathogens in Spain: Latest Data and Changes over 11 Years (1996-1997 to 2006-2007). <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2953-2959.	3.2	86
248	Reply to Tarchini. <i>Clinical Infectious Diseases</i> , 2010, 51, 120-121.	5.8	38
249	Clinical Features of Infections and Colonization by < i>Acinetobacter Genospecies 3. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4623-4626.	3.9	12
250	SmaqnR, a new chromosome-encoded quinolone resistance determinant in Serratia marcescens. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 239-242.	3.0	29
251	Isolation of multidrug-resistant Klebsiella oxytoca carrying blaIMP-8, associated with OXY hyperproduction, in the intensive care unit of a community hospital in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1071-1073.	3.0	16
252	Diversity of Escherichia coli Strains Producing Extended-Spectrum ß-Lactamases in Spain: Second Nationwide Study. <i>Journal of Clinical Microbiology</i> , 2010, 48, 2840-2845.	3.9	86

#	ARTICLE	IF	CITATIONS
253	Community-onset Bacteremia Due to Extended-spectrum β -lactamase-producing <i>Escherichia coli</i> : Risk Factors and Prognosis. <i>Clinical Infectious Diseases</i> , 2010, 50, 40-48.	5.8	294
254	Long-Term Control of Endemic Hospital-Wide Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA): The Impact of Targeted Active Surveillance for MRSA in Patients and Healthcare Workers. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 786-795.	1.8	31
255	A dynamic in vitro model for evaluating antimicrobial activity against bacterial biofilms using a new device and clinical-used catheters. <i>Journal of Microbiological Methods</i> , 2010, 83, 307-311.	1.6	8
256	Intracellular penetration and activity of UB-8902 in human polymorphonuclear leukocytes. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2010, 28, 612-614.	0.5	1
257	Prudent use of antimicrobials: Have we done the best we can? The SEIMC and REIPI statement. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2010, 28, 485-486.	0.5	6
258	Detection of Plasmid-Mediated Quinolone Resistance Genes in Clinical Isolates of <i>Enterobacter</i> spp. in Spain. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2033-2039.	3.9	53
259	Clinical Features and Molecular Epidemiology of CMY-type β -lactamase-producing <i>Escherichia coli</i> . <i>Clinical Infectious Diseases</i> , 2009, 48, 739-744.	5.8	45
260	Mutational analysis of quinolone resistance in the plasmid-encoded pentapeptide repeat proteins QnrA, QnrB and QnrS. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1128-1134.	3.0	36
261	Comment on: Redefining extended-spectrum β -lactamases: balancing science and clinical need. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 212-213.	3.0	18
262	<i>Escherichia coli</i> producing SHV-type extended-spectrum β -lactamase is a significant cause of community-acquired infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 781-784.	3.0	24
263	Eradication of an extensive outbreak in a neonatal unit caused by two sequential <i>Klebsiella pneumoniae</i> clones harbouring related plasmids encoding an extended-spectrum β -lactamase. <i>Journal of Hospital Infection</i> , 2009, 73, 157-163.	2.9	30
264	Genetic Variability among <i>ampC</i> Genes from <i>Acinetobacter</i> Genomic Species 3. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1177-1184.	3.2	21
265	A Multinational Survey of Risk Factors for Infection with Extended-spectrum β -lactamase-producing Enterobacteriaceae in Nonhospitalized Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 682-690.	5.8	415
266	Long-term control of hospital-wide, endemic multidrug-resistant <i>Acinetobacter baumannii</i> through a comprehensive β -bundle approach. <i>American Journal of Infection Control</i> , 2009, 37, 715-722.	2.3	88
267	Acquisition and Cross-Transmission of <i>Staphylococcus aureus</i> in European Intensive Care Units. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 117-124.	1.8	57
268	Colonization with Multiple <i>Staphylococcus aureus</i> Strains among Patients in European Intensive Care Units. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 918-920.	1.8	12
269	Risk-factors for emerging bloodstream infections caused by extended-spectrum β -lactamase-producing <i>Escherichia coli</i> . <i>Clinical Microbiology and Infection</i> , 2008, 14, 180-183.	6.0	95
270	Biofilm formation in <i>Acinetobacter baumannii</i> : associated features and clinical implications. <i>Clinical Microbiology and Infection</i> , 2008, 14, 276-278.	6.0	196

#	ARTICLE	IF	CITATIONS
271	Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of <i>Escherichia coli</i> resistant to cefoxitin. <i>Clinical Microbiology and Infection</i> , 2008, 14, 582-587.	6.0	3
272	Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by <i>Klebsiella pneumoniae</i> deficient in porins, expressing active efflux and producing QnrA1. <i>Clinical Microbiology and Infection</i> , 2008, 14, 691-697.	6.0	33
273	Plasmid-mediated quinolone resistance. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 685-711.	4.4	86
274	Clinical significance of extended-spectrum β -lactamases. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 671-683.	4.4	136
275	Effect of porin loss on the activity of tigecycline against <i>Klebsiella pneumoniae</i> producing extended-spectrum β -lactamases or plasmid-mediated AmpC-type β -lactamases. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 61, 343-345.	1.8	10
276	Detection and reporting β -lactam resistance phenotypes in <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> : a multicenter proficiency study in Spain. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 62, 317-325.	1.8	12
277	ComparaciÃ³n de tres mÃ©todos para determinar la sensibilidad a imipenem y meropenem en <i>Acinetobacter baumannii</i> con fenotipo heterorresistente a carbapenemes. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2008, 26, 485-488.	0.5	6
278	Update on bacterial pathogens: virulence and resistance. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2008, 26, 3-21.	0.5	0
279	< i>qnr Gene Nomenclature. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2297-2299.	3.2	192
280	Qnr-like pentapeptide repeat proteins in Gram-positive bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1240-1243.	3.0	60
281	Faecal carriage of extended-spectrum β -lactamase-producing <i>Escherichia coli</i> : prevalence, risk factors and molecular epidemiology. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1142-1149.	3.0	190
282	Neonatal sepsis caused by a CTX-M-32-producing <i>Escherichia coli</i> isolate. <i>Journal of Medical Microbiology</i> , 2008, 57, 1303-1305.	1.8	14
283	Characterization of the Carbapenem-Hydrolyzing Oxacillinase Oxa-58 in an <i>Acinetobacter</i> Genospecies 3 Clinical Isolate. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2955-2958.	3.2	30
284	Fatal Levofloxacin Failure in Treatment of a Bacteremic Patient Infected with < i>Streptococcus pneumoniae with a Preexisting < i>parC Mutation. <i>Journal of Clinical Microbiology</i> , 2008, 46, 1558-1560.	3.9	23
285	Community Infections Caused by Extended-Spectrum β -Lactamase-Producing <i>Escherichia coli</i> . <i>Archives of Internal Medicine</i> , 2008, 168, 1897.	3.8	333
286	Evaluation of the Etest method for fosfomycin susceptibility of ESBL-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 810-812.	3.0	20
287	False extended-spectrum β -lactamase detection in <i>Acinetobacter</i> spp. due to intrinsic susceptibility to clavulanic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 301-308.	3.0	10
288	Mutant Prevention Concentrations of Fluoroquinolones for Enterobacteriaceae Expressing the Plasmid-Carried Quinolone Resistance Determinant qnrA1. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2236-2239.	3.2	70

#	ARTICLE	IF	CITATIONS
289	The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 195-200.	1.8	6
290	Update on osteo-articular infections and severe skin and soft tissue infections. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2007, 25, 28-36.	0.5	0
291	Analysis of plasmids encoding extended-spectrum β -lactamases (ESBLs) from <i>Escherichia coli</i> isolated from non-hospitalised patients in Seville. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 89-92.	2.5	17
292	Characterisation of integrons containing the plasmid-mediated quinolone resistance gene qnrA1 in <i>Klebsiella pneumoniae</i> . <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 705-709.	2.5	26
293	Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in <i>Escherichia coli</i> and <i>Pseudomonas aeruginosa</i> biofilms. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 366-368.	2.5	55
294	Genotypic diversity of imipenem resistant isolates of <i>Acinetobacter baumannii</i> in Spain. <i>Journal of Infection</i> , 2007, 55, 260-266.	3.3	16
295	High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated <i>Acinetobacter baumannii</i> clinical isolates in Spain. <i>Clinical Microbiology and Infection</i> , 2007, 13, 1192-1198.	6.0	65
296	Prevalence of ISAbal in epidemiologically unrelated <i>Acinetobacter baumannii</i> clinical isolates. <i>FEMS Microbiology Letters</i> , 2007, 274, 63-66.	1.8	51
297	Prevention of rifampicin resistance in <i>Acinetobacter baumannii</i> in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 689-692.	3.0	45
298	In vivo selection of <i>Enterobacter aerogenes</i> with reduced susceptibility to cefepime and carbapenems associated with decreased expression of a 40kDa outer membrane protein and hyperproduction of AmpC β -lactamase. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 549-552.	2.5	26
299	Resistance to imipenem and zinc in clinical isolates of <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 377-378.	2.5	1
300	Comparative in vitro activity of ertapenem against extended-spectrum β -lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolated in Spain. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 457-459.	2.5	15
301	Bacteremia Due to Extended-Spectrum β -Lactamase-Producing <i>Escherichia coli</i> in the CTX-M Era: A New Clinical Challenge. <i>Clinical Infectious Diseases</i> , 2006, 43, 1407-1414.	5.8	251
302	Antimicrobial resistance in bacterial biofilms. <i>Reviews in Medical Microbiology</i> , 2006, 17, 65-75.	0.9	36
303	Susceptibility to amoxycillin-clavulanate among clinical isolates of <i>Escherichia coli</i> resistant to cefotixin. <i>Clinical Microbiology and Infection</i> , 2006, 12, 197-198.	6.0	2
304	Correlation of quinolone resistance levels and differences in basal and quinolone-induced expression from three qnrA-containing plasmids. <i>Clinical Microbiology and Infection</i> , 2006, 12, 440-445.	6.0	62
305	In Vitro Activity of Fosfomycin against Extended-Spectrum- β -Lactamase- Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> : Comparison of Susceptibility Testing Procedures. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 368-370.	3.2	95
306	Survival and resistance to imipenem of <i>Pseudomonas aeruginosa</i> on latex gloves. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 1010-1012.	3.0	7

#	ARTICLE	IF	CITATIONS
307	Characterization of a clinical isolate of <i>Haemophilus influenzae</i> with a high level of fluoroquinolone resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 577-578.	3.0	10
308	Plasmid-Mediated Quinolone Resistance in Australia. <i>Microbial Drug Resistance</i> , 2006, 12, 99-102.	2.0	30
309	Detection of Hypermutable <i>Escherichia coli</i> Strains in a Collection of Clinical Isolates by the Fosfomycin-Rifampin Disk Method. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2672-2672.	3.9	3
310	Intracellular Penetration and Activity of DX-619 in Human Polymorphonuclear Leukocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3173-3174.	3.2	10
311	Clinical and Molecular Epidemiology of Extended-Spectrum β -Lactamase-Producing <i>Escherichia coli</i> as a Cause of Nosocomial Infection or Colonization: Implications for Control. <i>Clinical Infectious Diseases</i> , 2006, 42, 37-45.	5.8	133
312	Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient <i>Klebsiella pneumoniae</i> producing FOX-5 β -lactamase. <i>Clinical Microbiology and Infection</i> , 2005, 11, 31-38.	6.0	7
313	Evaluation of antimicrobial susceptibility of bacteria containing the <i>qnr</i> gene and FOX-5 β -lactamase by four automated systems. <i>Clinical Microbiology and Infection</i> , 2005, 11, 402-404.	6.0	10
314	Long-term study of the frequency of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates producing extended-spectrum β -lactamases. <i>Clinical Microbiology and Infection</i> , 2005, 11, 625-631.	6.0	62
315	Risk-factors for the acquisition of imipenem-resistant <i>Acinetobacter baumannii</i> in Spain: a nationwide study. <i>Clinical Microbiology and Infection</i> , 2005, 11, 874-879.	6.0	102
316	Bacteremia caused by <i>Corynebacterium urealyticum</i> . <i>Clinical Microbiology Newsletter</i> , 2005, 27, 126-127.	0.7	0
317	Efficacy of Cefepime and Imipenem in Experimental Murine Pneumonia Caused by Porin-Deficient <i>Klebsiella pneumoniae</i> Producing CMY-2 β -Lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3311-3316.	3.2	13
318	Hyperproduction of AmpC β -lactamase in a clinical isolate of <i>Escherichia coli</i> associated with a 30-kbp deletion in the attenuator region of <i>ampC</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 251-252.	3.0	6
319	Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 785-787.	3.0	16
320	Nationwide Study of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Producing Extended-Spectrum β -Lactamases in Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2122-2125.	3.2	139
321	Zinc eluted from siliconized latex urinary catheters does not affect the in vitro activity of antifungal agents against <i>Candida</i> spp.. <i>International Journal of Antimicrobial Agents</i> , 2005, 26, 96-98.	2.5	1
322	Antimicrobial Susceptibility and Mechanisms of Resistance to Quinolones and β -Lactams in <i>Acinetobacter Genospecies 3</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1430-1432.	3.2	17
323	Characterization of the first CTX-M-14-producing <i>Salmonella enterica</i> serotype Enteritidis isolate. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 1113-1114.	3.0	31
324	Type 1 Integrrons in Epidemiologically Unrelated <i>Acinetobacter baumannii</i> Isolates Collected at Spanish Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 364-365.	3.2	30

#	ARTICLE	IF	CITATIONS
325	Use of Positive Blood Cultures for Direct Identification and Susceptibility Testing with the Vitek 2 System. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3734-3738.	3.9	82
326	Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of <i>Candida</i> . <i>Clinical Microbiology and Infection</i> , 2004, 10, 11-23.	6.0	333
327	Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia coli</i> in Nonhospitalized Patients. <i>Journal of Clinical Microbiology</i> , 2004, 42, 1089-1094.	3.9	395
328	Clinical Features and Epidemiology of <i>Acinetobacter baumannii</i> Colonization and Infection in Spanish Hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 819-824.	1.8	130
329	2004: un año trascendental para Enfermedades Infecciosas y Microbiología Clínica. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2004, 22, 1-2.	0.5	2
330	0,869: Primer factor de impacto de Enfermedades Infecciosas y Microbiología Clínica. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2004, 22, 373-373.	0.5	3
331	Evaluation of SDS-polyacrylamide gel systems for the study of outer membrane protein profiles of clinical strains of <i>Acinetobacter baumannii</i> . <i>Journal of Basic Microbiology</i> , 2003, 43, 194-201.	3.3	18
332	Evaluation of the WIDER I system for antimicrobial susceptibility testing of clinical isolates of <i>Haemophilus influenzae</i> and <i>Streptococcus pneumoniae</i> . <i>Clinical Microbiology and Infection</i> , 2003, 9, 449-452.	6.0	3
333	Infections by <i>Neisseria meningitidis</i> serogroup X in Spain. <i>Clinical Microbiology and Infection</i> , 2003, 9, 964-965.	6.0	10
334	Effect of siliconized latex urinary catheters on the activity of carbapenems against <i>Pseudomonas aeruginosa</i> strains with defined mutations in <i>ampC</i> , <i>oprD</i> , and genes coding for efflux systems. <i>International Journal of Antimicrobial Agents</i> , 2003, 22, 122-127.	2.5	15
335	Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 565-574.	3.0	199
336	Effect of Linezolid on the Phagocytic Functions of Human Polymorphonuclear Leukocytes. <i>Cancer Chemotherapy</i> , 2003, 49, 163-166.	1.6	11
337	Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 133-144.	1.1	113
338	Interaction of plasmid and host quinolone resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 1037-1039.	3.0	102
339	Zinc Eluted from Siliconized Latex Urinary Catheters Decreases OprD Expression, Causing Carbapenem Resistance in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2313-2315.	3.2	69
340	Detection of the plasmid-mediated quinolone resistance determinant <i>qnr</i> among clinical isolates of <i>Klebsiella pneumoniae</i> producing AmpC-type β -lactamase. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 703-706.	3.0	71
341	Activities of ABT-773 against <i>Listeria monocytogenes</i> and Coryneform Bacteria of Clinical Interest. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1403-1406.	3.2	3
342	Accumulation and activity of cethromycin (ABT-773) within human polymorphonuclear leucocytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 24-28.	3.0	11

#	ARTICLE	IF	CITATIONS
343	Role of <i>Klebsiella pneumoniae</i> OmpK35 Porin in Antimicrobial Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3332-3335.	3.2	141
344	In vitro Activity of Azithromycin in Combination with Amikacin, Ceftazidime, Ciprofloxacin or Imipenem against Clinical Isolates of <i>Acinetobacter baumannii</i> . <i>Chemotherapy</i> , 2003, 49, 24-26.	1.6	22
345	Escherichia coli y Klebsiella pneumoniae productores de betalactamasas de espectro extendido en hospitales espaÑoles (Proyecto GEIH-BLEE 2000). <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2003, 21, 77-82.	0.5	53
346	Bacteriemias por <i>Acinetobacter baumannii</i> : caracterÃsticas clÃnicas y pronÃ³sticas. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2003, 21, 242-247.	0.5	10
347	Actividad in vitro comparativa de garenoxacino (BMS-284756). Programa SENTRY EspaÑa (1999-2000). <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2003, 21, 404-409.	0.5	4
348	Hemocultivos y lÃquido cefalorraquÃdeo. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2003, 21, 37-43.	0.5	1
349	Uptake and Intracellular Activity of Linezolid in Human Phagocytes and Nonphagocytic Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 4013-4015.	3.2	24
350	Energy-Dependent Accumulation of Norfloxacin and Porin Expression in Clinical Isolates of <i>Klebsiella pneumoniae</i> and Relationship to Extended-Spectrum β -Lactamase Production. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3926-3932.	3.2	60
351	Comparison of an Assay Using Signal Amplification of the Heat-Dissociated p24 Antigen with the Roche Monitor Human Immunodeficiency Virus RNA Assay. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2472-2475.	3.9	38
352	Pathogenesis of catheter-related infections: lessons for new designs. <i>Clinical Microbiology and Infection</i> , 2002, 8, 256-264.	6.0	89
353	Hospital infection control in Spain. <i>Journal of Hospital Infection</i> , 2001, 48, 258-260.	2.9	13
354	Differences between Two New Quinolones (Gemifloxacin and Trovafloxacin) and Ciprofloxacin in Their Concentration-Dependent Killing of <i>Streptococcus pneumoniae</i> . <i>Chemotherapy</i> , 2001, 47, 409-414.	1.6	10
355	Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and non-phagocytic cells. <i>Clinical Microbiology and Infection</i> , 2001, 7, 65-69.	6.0	23
356	In Vitro Adherence of <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> to Urinary Catheters. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2000, 19, 124-127.	2.9	41
357	Activity of nine antimicrobial agents against clinical isolates of <i>Klebsiella pneumoniae</i> producing extended-spectrum beta-lactamases and deficient or not in porins. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 858-860.	3.0	19
358	Activities of Imipenem and Cephalosporins against Clonally Related Strains of <i>Escherichia coli</i> Hyperproducing Chromosomal β -Lactamase and Showing Altered Porin Profiles. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2534-2536.	3.2	75
359	Trends in the susceptibilities of <i>Proteus mirabilis</i> isolates to quinolones. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 45, 407-408.	3.0	20
360	Relationship between outer membrane alterations and susceptibility to antimicrobial agents in isogenic strains of <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 46, 273-277.	3.0	79

#	ARTICLE	IF	CITATIONS
361	Intracellular Penetration and Activity of Gemifloxacin in Human Polymorphonuclear Leukocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3193-3195.	3.2	22
362	Uptake and intracellular activity of ofloxacin isomers in human phagocytic and non-phagocytic cells. <i>International Journal of Antimicrobial Agents</i> , 2000, 15, 201-205.	2.5	24
363	Roles of β -Lactamases and Porins in Activities of Carbapenems and Cephalosporins against <i>< i> Klebsiella pneumoniae </i></i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1669-1673.	3.2	238
364	Development of Resistance during Antimicrobial Therapy Caused by Insertion Sequence Interruption of Porin Genes. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 937-939.	3.2	87
365	Uptake and Intracellular Activity of Moxifloxacin in Human Neutrophils and Tissue-Cultured Epithelial Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 12-15.	3.2	58
366	In-vitro activity of levofloxacin, ofloxacin and d -ofloxacin against coryneform bacteria and Listeria monocytogenes. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 43, 27-32.	3.0	22
367	In vitro adherence of <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> to plastic biomaterials. <i>Clinical Microbiology and Infection</i> , 1999, 5, 382-386.	6.0	25
368	Resistance of <i>< i> Pseudomonas aeruginosa </i></i> to Imipenem Induced by Eluates from Siliconized Latex Urinary Catheters Is Related to Outer Membrane Protein Alterations. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 397-399.	3.2	28
369	Quinolone resistance from a transferable plasmid. <i>Lancet</i> , The, 1998, 351, 797-799.	13.7	980
370	Energy-Dependent Accumulation of Fluoroquinolones in Quinolone-Resistant <i>< i> Klebsiella pneumoniae </i></i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 1850-1852.	3.2	46
371	In Vitro Activities of Ketolide HMR 3647, Macrolides, and Clindamycin against Coryneform Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 3290-3292.	3.2	20
372	In-vitro susceptibilities of multiresistant strains of <i>Acinetobacter baumannii</i> to eight quinolones. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 140-142.	3.0	10
373	Comparison of three methods of determining the in-vitro susceptibilities of <i>Acinetobacter baumannii</i> isolates to imipenem. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 742-743.	3.0	4
374	Azithromycin uptake by tissue cultured epithelial cells. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 39, 293-295.	3.0	16
375	Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 274-277.	3.2	51
376	Evolution of the antimicrobial susceptibility of <i>B. fragilis</i> group at the university hospital of Seville (Spain) between 1977 and 1995. <i>International Journal of Antimicrobial Agents</i> , 1996, 7, 1-7.	2.5	3
377	Antimicrobial susceptibility pattern of <i>Corynebacterium striatum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1996, 40, 2671-2672.	3.2	42
378	Effect of Phagocytosis of Bacteria on the Uptake of Sparfloxacin by Human Neutrophils. <i>Chemotherapy</i> , 1996, 42, 465-467.	1.6	0

#	ARTICLE	IF	CITATIONS
379	Comparative in-vitro activity of sparfloxacin against genital pathogens. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 37, 19-25.	3.0	17
380	In-vitro activity of antimicrobial agent combinations against multiresistant <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 1107-1108.	3.0	34
381	Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 859-863.	3.0	10
382	Comparison of broth microdilution and E-test for susceptibility testing of <i>Neisseria meningitidis</i> . <i>Journal of Clinical Microbiology</i> , 1996, 34, 588-591.	3.9	22
383	Uptake and intracellular activity of antimicrobial agents in phagocytic cells. <i>Reviews in Medical Microbiology</i> , 1995, 6, 228-235.	0.9	20
384	Activity of sparfloxacin on <i>Staphylococcus epidermidis</i> attached to plastic catheters. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 36, 425-430.	3.0	12
385	Factors affecting the intracellular accumulation and activity of azithromycin. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 35, 85-93.	3.0	38
386	Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 1994, 38, 2426-2429.	3.2	24
387	Effects of antimicrobial and antineoplastic drugs on the uptake of sparfloxacin by human neutrophils. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 34, 171-174.	3.0	5
388	Activity of eight antibacterial agents on <i>Staphylococcus epidermidis</i> attached to Teflon catheters. <i>Journal of Medical Microbiology</i> , 1994, 40, 43-47.	1.8	45
389	Urinary tract infection caused by quinolone-resistant <i>Campylobacter coli</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1994, 13, 690-691.	2.9	1
390	Activity of glycopeptides in combination with amikacin or rifampin against <i>Staphylococcus epidermidis</i> biofilms on plastic catheters. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1994, 13, 515-517.	2.9	29
391	Late onset Papillon-Lefevre syndrome?. A chromosomal, neutrophil function and microbiological study. <i>Journal of Clinical Periodontology</i> , 1993, 20, 662-667.	4.9	59
392	Effect of antimicrobial and antineoplastic drugs on the uptake of fluconazole by human neutrophils and tissue culture cells. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1993, 12, 944-947.	2.9	1
393	Susceptibility to antimicrobial agents of <i>Pseudomonas aeruginosa</i> attached to siliconized latex urinary catheters. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1993, 12, 761-765.	2.9	12
394	Effect of polyurethane catheters and bacterial biofilms on the in-vitro activity of antimicrobials against <i>Staphylococcus epidermidis</i> . <i>Journal of Hospital Infection</i> , 1993, 24, 211-218.	2.9	58
395	Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 37, 187-190.	3.2	33
396	Intraphagocytic Cell Penetration and Intracellular Bioactivity of Antibiotics. , 1993, , 965-970.	0	

#	ARTICLE	IF	CITATIONS
397	Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. <i>Antimicrobial Agents and Chemotherapy</i> , 1992, 36, 1053-1056.	3.2	53
398	Entry of lomefloxacin and temafloxacin into human neutrophils, peritoneal macrophages, and tissue culture cells. <i>Diagnostic Microbiology and Infectious Disease</i> , 1992, 15, 393-398.	1.8	13
399	Comparative penetration of lomefloxacin and other quinolones into human phagocytes. <i>American Journal of Medicine</i> , 1992, 92, S48-S51.	1.5	35
400	Effect of several antimicrobial agents on ciprofloxacin uptake by human neutrophils. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1992, 11, 260-262.	2.9	4
401	The effect of stainless steel, cobalt-chromium, titanium alloy, and titanium on the respiratory burst activity of human polymorphonuclear leukocytes. <i>Clinical Orthopaedics and Related Research</i> , 1992, , 281-8.	1.5	3
402	Effect of a siliconized latex urinary catheter on bacterial adherence and human neutrophil activity. <i>Diagnostic Microbiology and Infectious Disease</i> , 1991, 14, 1-6.	1.8	18
403	Evaluation of a DNA probe of plasmid origin for the detection of <i>Chlamydia trachomatis</i> in cultures and clinical specimens. <i>Molecular and Cellular Probes</i> , 1991, 5, 419-427.	2.1	5
404	Effect of plastic catheter material on bacterial adherence and viability. <i>Journal of Medical Microbiology</i> , 1991, 34, 349-353.	1.8	94
405	Effect of antimicrobial agents on the uptake of ofloxacin and its optically active isomer (â€œ)-ofloxacin by human polymorphonuclear leucocytes. <i>Journal of Antimicrobial Chemotherapy</i> , 1991, 28, 727-730.	3.0	4
406	Effect of Preincubation of <i>< i>Pseudomonas aeruginosa</i></i> in Subinhibitory Concentrations of Amikacin, Ceftazidime and Ciprofloxacin on Adherence to Plastic Catheters. <i>Chemotherapy</i> , 1991, 37, 62-65.	1.6	4
407	Effect of Ampicillin/Sulbactam on Human Polymorphonuclear Leukocyte Function. <i>Chemotherapy</i> , 1991, 37, 335-342.	1.6	4
408	Fluorometric and high-performance liquid chromatographic measurement of quinolone uptake by human neutrophils. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1991, 10, 969-971.	2.9	30
409	Kinetics of adherence of mucoid and non-mucoid <i>pseudomonas aeruginosa</i> to plastic catheters. <i>Journal of Medical Microbiology</i> , 1991, 34, 7-12.	1.8	45
410	Effect of Azithromycin, Roxithromycin and Erythromycin on Human Polymorphonuclear Leukocyte Function against <i>< i>Staphylococcus aureus</i></i> . <i>Chemotherapy</i> , 1990, 36, 422-427.	1.6	13
411	Comparison of two direct fluorescent antibody techniques and cell culture for the detection of <i>Chlamydia trachomatis</i> . <i>Serodiagnosis and Immunotherapy in Infectious Disease</i> , 1990, 4, 427-430.	0.2	0
412	Effect of clavulanic acid and beta-lactamase on phagocytosis of <i>Staphylococcus aureus</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1990, 9, 783-784.	2.9	1
413	Effect of plastic catheters on the phagocytic activity of human polymorphonuclear leukocytes. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1990, 9, 324-328.	2.9	7
414	Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells. <i>Antimicrobial Agents and Chemotherapy</i> , 1990, 34, 277-280.	3.2	59

#	ARTICLE	IF	CITATIONS
415	Surface Proteins of Coagulase-Negative Staphylococci: Their Role in Adherence to Biomaterials and in Opsonization. <i>Journal of Biomaterials Applications</i> , 1990, 5, 154-165.	2.4	11
416	Effect of three plastic catheters on survival and growth of <i>Pseudomonas aeruginosa</i> . <i>Journal of Hospital Infection</i> , 1990, 16, 311-318.	2.9	32
417	Fluorometric measurement of ofloxacin uptake by human polymorphonuclear leukocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 1989, 33, 653-656.	3.2	86
418	Effect of amoxycillin and clavulanic acid, alone and in combination, on human polymorphonuclear leukocyte function against <i>Staphylococcus aureus</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1989, 8, 277-281.	2.9	16
419	Effect of Ciprofloxacin and Ofloxacin on Human Polymorphonuclear Leukocyte Activity against Staphylococci. <i>Chemotherapy</i> , 1989, 35, 17-22.	1.6	14
420	Surface hydrophobicity and opsonic requirements of coagulase-negative staphylococci in suspension and adhering to a polymer substratum. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1988, 7, 161-166.	2.9	20
421	Comparative in-vitro activity of cefodizime, cefpirome, carumonam and RU-28965 with other antimicrobials against anaerobes. <i>Journal of Antimicrobial Chemotherapy</i> , 1987, 19, 701-703.	3.0	3
422	Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1987, 6, 152-157.	2.9	63
423	Coagulase-negative staphylococci as nosocomial pathogens in neonates: The role of host defense, artificial devices, and bacterial hydrophobicity. <i>American Journal of Medicine</i> , 1986, 80, 161-165.	1.5	107
424	Modulation of adherence of coagulase-negative staphylococci to teflon catheters in vitro. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1986, 5, 518-522.	2.9	152
425	Effect of medium, pH, and inoculum size on activity of ceftizoxime and Sch-34343 against anaerobic bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 1986, 30, 626-627.	3.2	24
426	Increasing resistance of <i>Bacteroides fragilis</i> group strains to metronidazole in Spain between 1977 and 1982. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1984, 3, 153-155.	2.9	16
427	N-formimidoyl-thienamycin activity against anaerobes: effect of the inoculum, pH and culture media. <i>Journal of Antimicrobial Chemotherapy</i> , 1981, 8, 213-218.	3.0	10
428	CARB-ES-19 Multicenter Study of Carbapenemase-Producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3. <i>Frontiers in Microbiology</i> , 0, 13, .	3.5	20